Noramco announced the addition of 23 new compounds to its analytical reference standards catalog – compounds pharmaceutical product developers require to validate product quality and to verify the integrity of production systems…
Noramco at DCAT Week 2018
Meet Noramco at DCAT Week ’18, to be held March 19-22, New York, NY. Come talk to us about Cannabinoids, Clinical and Custom Solutions, Product Conversion, and what we are doing in the ADHD Space. DCAT Week is the premier business development event for companies engaged in pharmaceutical development…
Noramco introduces controlled substance development solutions at CPhI Worldwide
Noramco is integrating its API development offering to include all of the technologies and services that generic and branded pharmaceutical producers require to advance solutions to market. The specialty API producer today introduced a comprehensive…
Noramco and SPI Pharma sign letter of intent to develop formulation solution packages
Noramco, a global leader in the manufacture and supply of controlled substance active pharmaceutical ingredients, and SPI Pharma, a global leader in the manufacture and supply of functional excipient platforms and drug development services…
Noramco introduces a turnkey approach to cannabinoid APIs at CPhI Worldwide
Noramco is moving forward with a broad offering of clinical- to commercial-scale cannabinoid APIs for branded and generic pharmaceuticals. The comprehensive offering includes everything a drug manufacturer requires to advance cannabinoid-based APIs to finished dosage forms.
Noramco Celebrates “One Year Strong”
On July 1st Noramco marked its first full year as an independent company. To celebrate the milestone, the President and CEO, James Mish, sponsored #OneYearStrong luncheons at facilities in Athens, Georgia; Wilmington, Delaware; and Neuhausen, Switzerland.
Noramco Moves European R&D and Logistics Teams to New Facility
Research and logistics professionals responsible for Noramco’s European operations now operate out of a new facility in Neuhausen, Switzerland. Approximately 30 employees work at the state-of-the-art center…
Noramco’s Joshua Hoerner Cited in New Study Determining Genotoxic Impurities, DMS and MMS
Researchers at Noramco study analytical methods to detect and determine the presence of potentially genotoxic impurities (PGIs) in pharmaceutical products.
Noramco to attend AAPS
Why is Noramco leveraging expertise in APIs to provide solutions to stability, bioavailability, and purity challenges?
Noramco to attend CPhI in Frankfurt Germany
Meet us at CPhI Worldwide for more information about “one-stop API development and manufacturing.”